Name (Synonyms) | Correlation | |
---|---|---|
drug2815 | TERN-101 Wiki | 1.00 |
drug2122 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D065626 | Non-alcoholic Fatty Liver Disease NIH | 1.00 |
D005234 | Fatty Liver NIH | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.
Description: Area under the curve
Measure: Plasma concentration of TERN-101 - AUC Time: 12 weeksDescription: Maximum observed concentration
Measure: Plasma concentration of TERN-101 - Cmax Time: 12 weeksDescription: Time to reach maximum measured plasma concentration
Measure: Plasma concentration of TERN-101 - Tmax Time: 12 weeksDescription: Determination of half-life
Measure: Plasma concentration of TERN-101 - t1/2 Time: 12 weeks